Awareness of Genomic Risk for Melanoma May Increase Conversations With Family, Health Care ProvidersAugust 11, 2017
Awareness of personal genetic risk for melanoma may prompt patients to discuss cancer risk with family and health care professionals, and make lifestyle changes.
Many women with breast cancer with genetic variants of uncertain significance (VUS) undergo testing and bilateral mastectomy without receiving genetic counseling.
Many women with breast cancer with genetic VUS undergo testing and bilateral mastectomy (BLM) without ever receiving genetic counseling.
As molecular testing becomes the standard of care for many cancers, nurse navigators have an important role to play ensuring molecular testing of suitable patients, providing patient education, and managing of patient expectations.
Some men who undergo multigene testing for inherited prostate cancer misinterpret findings of variants of uncertain significance.
A questionnaire added to intake forms at a breast cancer imaging center identified women with BRCA mutations who might otherwise have been missed.
Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer RiskApril 19, 2017
Whole genome sequencing of more than 3000 survivors of childhood cancers demonstrates the value of genetic testing for potential second cancers in this population.
Two-gene pigmented lesion test classifies skin lesions as melanoma or nonmelanoma, helping with diagnostic challenges faced with the visual image and pattern recognition approach.
Progression-free survival rates are higher in patients treated with targeted therapies based on results of multigene panel tests.
Genetic testing for BRCA gene mutation is increasingly undertaken by women unaffected by breast and/or ovarian cancers.
A head-to-head comparison of two commercial gene sequencing tests yielded differing results.
Rapid, robust, and affordable genetic testing for patients with ovarian cancer that allows a much larger portion of patients to benefit from personalized cancer management and their relatives to benefit from preventive strategies can be achieved.
Disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors underscores that "the benefit from genetic testing comes from acting on the test results," not just the testing itself, a study presented at the ASCO 2016 Annual Meeting concluded.
Multiplex gene testing of diverse patients has found that patients who test positive advise relatives to test, "suggesting that participants understood the implications of test results," according to results of a planned interim analysis of a prospective trial presented at the ASCO 2016 Annual Meeting.
"In the absence of patient-matched germline data, large germline databases are required in analysis workflows to minimize false positive mutation calling and mitigate ethnic disparities," a study presented at the ASCO 2016 Annual Meeting concluded.
Results showed that telephone disclosure was not worse than in-person disclosure for general and state anxiety.
No Clinical Benefit to Expanding Gene Panel Beyond Ovarian and Breast Cancer Genes in High-risk WomenMay 20, 2016
Expanding a panel of tested genes beyond the known breast and ovarian cancer-specific genes in patients with breast and ovarian cancer did not confer any clinical benefit.
An analysis of test results can help women who won't benefit from additional treatment avoid potential side effects.
Among women age 40 years or younger, rates of genetic testing for BRCA1 and BRCA2 mutations have increased, according to a recent study.
Young patients with HER2+ breast cancer and no family history have low risk of carrying high risk genesDecember 29, 2015
A recent study examined genetic susceptibility in younger patients diagnosed with HER2+ breast cancer.
A stool DNA test for colorectal cancer was found to be an accurate noninvasive screening option for Alaska Native people, a population with one of the highest rates of colorectal cancer in the world, according to a recent study.
A widely available, inexpensive blood test can predict outcomes and guide treatment in pancreatic cancer; however, only 1 in 5 US patients with the disease have the blood test.
A new study has uncovered four new genetic variants associated with increased risk of testicular cancer. Testing for these and all 21 previously identified variants using genetic sequencing identified men at higher risk of testicular cancer.
Use of chemotherapy is inverse to disease risk in patients with breast cancer when genetic assay is usedSeptember 23, 2015
Use of the 21-gene recurrence test score was associated with lower chemotherapy use in high-risk patients and greater use of chemotherapy in low-risk patients compared with not using the test score among a large group of Medicare beneficiaries, according to a recent investigation.
Multigene testing of women negative for BRCA1 and BRCA2 uncovered other harmful genetic mutations.
New research indicates that many genetic alterations identified using tumor-only sequencing are not actually associated with the cancer, but instead reflect inherited germline mutations already present in the normal cells of the person.
Women with ovarian cancer should be tested for BRCA1 and BRCA2 gene mutations, regardless of their family history.
Near one quarter of patients with advanced lung cancer in Europe, Asia, and the United States are not receiving EGFR test results before being started on treatment, researchers found.
For many women with breast cancer, there is concern about the genetic risk of developing other cancers themselves or of a loved one developing cancer.
Most cancer patients want tumor profiling, but have mixed feelings about other genetic information the tests may revealApril 22, 2015
A majority of patients with cancer desire tumor profiling, even if the test would reveal risks for other genetic diseases.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Coping With Lymphedema: A Patient Guide (Fact Sheet)
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|